RIPK3 and chronic obstructive pulmonary disease: RIPK3 decreased proportionally to the CSE dose (Supplementary Materials, Figure S3B,D) rather than increased as observed in the lung of COPD patients and mice exposed to CS (Supplementary Materials, Figure S2A,C,D,F).